Who Paid My Doc
James Gainer
Hypertension Specialist Nashville, TN Medical Doctor
NPI 1467544874 CMS profile 775088
719 Thompson Ln Ste 38500, Nashville, TN 37204
General payments
$28,245
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, James Gainer of Nashville, TN is reported in the CMS Open Payments database as having received $28,245 across 31 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $9,704 | 13 | |
| 2024 | General | $18,362 | 17 | |
| 2023 | General | $180 | 1 |
Beside peers
- James Gainer
- Tennessee median
- Middle half of Tennessee
- National median
In program year 2025, general payments to James Gainer were reported at $9,704. Among 24,836 Tennessee profiles paid that year, the median was $199 and the middle half received between $54 and $728.
Show as a table
| Year | James Gainer | Tennessee median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $197 | $58–$789 | $163 |
| 2020 | $0 | $132 | $38–$484 | $114 |
| 2021 | $0 | $145 | $39–$541 | $132 |
| 2022 | $0 | $170 | $50–$642 | $149 |
| 2023 | $180 | $183 | $50–$668 | $160 |
| 2024 | $18,362 | $187 | $51–$700 | $164 |
| 2025 | $9,704 | $199 | $54–$728 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 100 drugsPart D claims
5,515
Drug cost
$346,029
Branded share of claims
17.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 70 | $74,977 | |
| Jardiance Empagliflozin | Brand | 51 | $50,414 | |
| Eliquis Apixaban | Brand | 50 | $43,729 | |
| Eplerenone | Generic | 191 | $24,699 | |
| Mounjaro Tirzepatide | Brand | 17 | $17,632 | |
| Gemtesa Vibegron | Brand | 14 | $13,764 | |
| Oxymorphone Hcl Er Oxymorphone Hcl | Brand | 13 | $8,842 | |
| Myrbetriq Mirabegron | Brand | 12 | $7,533 | |
| Repatha Sureclick Evolocumab | Brand | 13 | $6,916 | |
| Benicar Olmesartan Medoxomil | Brand | 12 | $6,749 |
The 10 drugs with the highest cost, of 100 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 22 billing codesPaid by Medicare
$48,624
Medicare patients
247
Services billed
734
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 52% | |
| Chronic kidney disease | 36% | |
| Diabetes | 30% | |
| Ischemic heart disease | 27% | |
| Atrial fibrillation | 21% | |
| Osteoporosis | 19% | |
| Depression | 18% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
31 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hypertension Specialist in Tennessee
Related records
Hypertension Specialist in Tennessee
Practitioners in the same specialty and state, ranked by reported value.
All Hypertension Specialist
Everyone recorded under this specialty, nationwide.
Doctors in Tennessee
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.